Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Reinhard Dummer*a, Marc Beyer*b, Kenneth Hymesc, Mirjam T. Eppingd, Rene Bernardsd, Matthias Steinhoffb, Wolfram Sterryb, Helmut Kerle, Karl Heathf, Janet D. Ahernf, James S. Hardwickf, Jose Garcia-Vargasf, Katrin Baumanna, Syed Rizvif, Stanley R. Frankelf, Sean J. Whittakerg & Chalid Assafbha University Hospital Zürich, Switzerlandb Charitè-Universitätsmedizin, Berlin, Germanyc New York University Clinical Cancer Center, NY, USAd The Netherlands Cancer Institute, Amsterdam, The Netherlandse Medical University of Graz, Austriaf Columbia University, New York, NY, USAg King's College London, UKh Helios Klinikum, Krefeld, GermanyCorrespondence: Dr. Reinhard Dummer, University Hospital Zürich, Department of Dermatology, Gloriastrasse 31, CH-8091, Zürich, Switzerland. Tel: + 41-1-255-1111. Fax: + 41-1-255-9032. E-mail: reinhard.dummer@usz.chDr. Marc Beyer, Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy, Skin Cancer Center Charité, Charitéplatz 1, 10117, Berlin, Germany. Tel: + 49-30-450618369. Fax: + 49-30-450518949. E-mail: marc.beyer@charite.deAbstractThe retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs). We investigated the combination of HDACI and retinoic acid receptor (RAR)/RXR agonists in vitro and in a phase I, multicenter, open-label, two-part dose-escalation study. The combination of bexarotene with a HDACI in vitro leads to cooperative activation of gene transcription and reduction of cell viability in human tumor cell lines. The primary clinical objective was to determine the maximum tolerated dose (MTD) of bexarotene plus vorinostat in 23 patients with CTCLs. The MTD for part I was established at vorinostat 200 mg/day plus bexarotene 300 mg/m2/day. The MTD for part II was not reached. Four patients had an objective response and seven patients experienced pruritus relief. We conclude that concomitant administration of vorinostat and bexarotene is feasible only if lower doses of each drug are administered relative to the product label monotherapy doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Self-citationThe promise of retinoids to fight against cancer
Altucci, L., & Gronemeyer, H. (2001) · Nature Reviews Cancer · doi:10.1038/35106036 · Cited by 773
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Self-citationSchug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N., & Noy, N. (2007) · Cell · doi:10.1016/j.cell.2007.02.050 · Cited by 680
International Union of Pharmacology. LXIII. Retinoid X receptors
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., & Gronemeyer, H. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.7 · Cited by 496
Cited by
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.049 · Cited by 381
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.08.033 · Cited by 347
Dheer, Y., Chitranshi, N., Gupta, V., Abbasi, M., Mirzaei, M., You, Y., Chung, R., Graham, S. L., & Gupta, V. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1041-9 · Cited by 63
Metadata
- Authors
- Dummer, R., Beyer, M., Hymes, K., Epping, M. T., Bernards, R., Steinhoff, M., Sterry, W., Kerl, H., Heath, K., Ahern, J. D., Hardwick, J. S., Garcia-Vargas, J., Baumann, K., Rizvi, S., Frankel, S. R., Whittaker, S. J., & Assaf, C.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2012-02-13
- Volume
- 53
- Issue
- 8
- Pages
- 1501-1508
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W1993366417
- Cited by
- 65
- References
- 5
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. https://app.cochat.ai/papers/10.3109/10428194.2012.656625
- The paper
- Dummer, R., Beyer, M., Hymes, K., Epping, M. T., Bernards, R., Steinhoff, M., Sterry, W., Kerl, H., Heath, K., Ahern, J. D., Hardwick, J. S., Garcia-Vargas, J., Baumann, K., Rizvi, S., Frankel, S. R., Whittaker, S. J., & Assaf, C. (2012). Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia & Lymphoma. https://doi.org/10.3109/10428194.2012.656625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.